SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immucor

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mason Barge who wrote (185)9/7/1998 10:24:00 AM
From: Thomas Kirwin  Read Replies (1) of 422
 
Mason,

I agree that sales and exposure will be key elements in the fuel that makes Immucor blast off.

The IBD funds data may be misleading. You see, each issue of the Investor's Business Daily includes different data. It encourages investors to buy the paper on a regular basis. The last two issues purchased did not include the # Of Funds Own column. The data was printed in this Monday's issue. I seriously doubt that seven new funds added Immucor to their individual portfolios.

IMHO - The stock price strength is the result of the repurchase program success and possible good news.

Regards,

Tom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext